Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors

PRIMARY OBJECTIVES:

I. To determine the neuropharmacokinetic (nPK) profile of eribulin (eribulin mesylate) using
intracerebral microdialysis.

SECONDARY OBJECTIVES:

I. To compare concentrations of eribulin in tumor (enhancing tissue) and normal brain
(non-enhancing tissue) when technically feasible to place two microdialysis catheters in a
study patient.

II. To describe the intracerebral clinical benefit (defined as stable disease, partial
response, or complete response) of eribulin in study patients who continue to be treated with
eribulin after completing the microdialysis portion of the study.

III. To document the toxicity of eribulin in the cohort of patients.

OUTLINE:

Patients undergo tumor resection or biopsy and have microdialysis catheter placed on day 0.
Beginning at least 24 hours later, patients receive eribulin mesylate intravenously (IV) over
2-5 minutes on day 1. Serial brain fluid samples are collected for approximately 72 hours and
the microdialysis catheter is then removed. Beginning at least 2 weeks after tumor resection
or biopsy, patients may continue to receive eribulin mesylate IV over 2-5 minutes on days 1
and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable
toxicity.

After completion of study treatment, patients are followed up for 30 days.

Inclusion Criteria:

- Patients must have a Karnofsky performance status of >= 60

- Brain tumor patient is planning to undergo tumor resection or biopsy for the purpose
of differentiating between tumor progression versus treatment-induced effects
following radiation therapy and/or chemotherapy

* If a patient has magnetic resonance imaging (MRI) findings consistent with tumor but
does not already have a histopathologic diagnosis of cancer, s/he may sign the consent
form, but final eligibility for study enrollment will be determined based on results
of the frozen section at time of surgery

- Patient may have received previous treatment for the brain tumor(s), including
radiation (focal brain radiation, whole brain radiation or stereotactic radiosurgery),
surgery or chemotherapy

- There is no limit to the number of prior chemotherapies

- Patients who have previously been treated with eribulin are allowed to participate in
the microdialysis portion of the study only

- Absolute neutrophil count of > 1500 cells/mm^3

- Platelet count > 100,000 cells/mm^3

- Total bilirubin < 2.0 mg/dl

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) < 3
times the institutional upper limit of normal

- Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 3
times the institutional upper limit of normal

- Serum creatinine < 1.5 x the institutional upper limit of normal

- All subjects must have the ability to understand and the willingness to sign a written
informed consent

- Patients must have sufficiently recovered (=< grade 1) from any toxicity of prior
therapy; the required waiting period between the last dose of the most recent
chemotherapy agent and the first dose of eribulin will be determined based on the
half-life of the chemotherapy agent; the minimum time between stopping prior therapy
and administering the first dose of eribulin should be 3.3 half-lives with the
following exceptions: an interval of at least 6 weeks must elapse since treatment with
a nitrosourea and at least 4 weeks since the last dose of bevacizumab

- If corticosteroids are required for controlling cerebral edema, patients must be on a
stable dose of at least 1 week prior to enrollment

- Women of child-bearing potential must agree to use adequate contraception (hormonal or
barrier method of birth control or abstinence) prior to study entry and for 3 months
following duration of study participation; women of child-bearing potential must have
a negative serum pregnancy test prior to enrollment; should a woman become pregnant or
suspect that she is pregnant while participating on the trial, she should inform her
treating physician immediately

Exclusion Criteria:

- Patients who are currently receiving chemotherapy, radiation therapy or are enrolled
in another therapeutic clinical trial

- Patients who have not recovered from the toxicities of prior chemotherapy or radiation

- Patients who are taking any of the prohibited medications; if a patient is willing to
discontinue such a medication in order to participate in the study, then there must be
an appropriate washout period, based on the half-life of the particular drug, prior to
the start of the study treatment

- Clinically evident congestive heart failure > class II of the New York Heart
Association (NYHA) guidelines, unstable angina or myocardial infarction within the
previous 6 months

- Clinically significant cardiac arrhythmias, prolonged QT interval, congenital long QT
syndrome

- Patients who cannot undergo brain magnetic resonance imaging (MRIs)

- Patients with existing grade 3 or 4 peripheral neuropathy

- Patients who have a serious medical or psychiatric illness that could, in the
investigator's opinion, potentially interfere with the completion of treatment
according to this protocol or may not be able to comply with the safety monitoring
requirements of the study

- Female patients who are pregnant or breast-feeding

- Active, clinically significant serious infection requiring treatment with antibiotics,
anti-virals or anti-fungals

- Non-compliance: subjects who in the opinion of the investigator, may not be able to
comply with the safety monitoring requirements of the study